The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Robert J. DelAversano, insider at OncoSec Medical

Robert J. DelAversano Insider Information

Mr. DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public accounting.
Prior to this appointment as OncoSec’s Principal Accounting Officer and Controller, Mr. DelAversano served as OncoSec’s Executive Director of Finance since 2018 where he had global responsibility for accounting, external financial reporting, and financial controls covering all aspects of OncoSec’s business. Prior to joining OncoSec, he was the Director of Financial Reporting and Taxation at Brio Financial Group (“Brio”), consulting with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC and oversaw their accounting and tax practice with industry focuses in manufacturing, wholesalers and medical devices services. In addition, he performed audit services, outsourced chief financial officer functions, and consulted clients through difficult Securities and Exchange Commission comment periods particularly through application of complex accounting principles for a large public company client base.

Mr. DelAversano holds a bachelor’s degree in Accounting from Rider University.

What is Robert J. DelAversano's net worth?

The estimated net worth of Robert J. DelAversano is at least $16,922.52 as of August 5th, 2022. Mr. DelAversano owns 23,258 shares of OncoSec Medical stock worth more than $16,923 as of August 10th. This net worth approximation does not reflect any other assets that Mr. DelAversano may own. Additionally, Mr. DelAversano receives an annual salary of $361,180.00 as VP at OncoSec Medical. Learn More about Robert J. DelAversano's net worth.

How old is Robert J. DelAversano?

Mr. DelAversano is currently 50 years old. There are 3 older executives and no younger executives at OncoSec Medical. Learn More on Robert J. DelAversano's age.

What is Robert J. DelAversano's salary?

As the VP of OncoSec Medical Incorporated, Mr. DelAversano earned a total compensation package of $578,399.00 in 2021. Mr. DelAversano earned a salary of $270,285.00, a bonus of $83,500.00, stock awards of $66,850.00, options awards of $150,373.00, and other compensation of $7,391.00. Learn More on Robert J. DelAversano's salary.

How do I contact Robert J. DelAversano?

The corporate mailing address for Mr. DelAversano and other OncoSec Medical executives is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. OncoSec Medical can also be reached via phone at (858) 662-6732 and via email at [email protected] Learn More on Robert J. DelAversano's contact information.

Has Robert J. DelAversano been buying or selling shares of OncoSec Medical?

During the past quarter, Robert J. DelAversano has sold $201.64 in OncoSec Medical stock. Most recently, Robert J. Delaversano sold 284 shares of the business's stock in a transaction on Friday, August 5th. The shares were sold at an average price of $0.71, for a transaction totalling $201.64. Following the completion of the sale, the vice president now directly owns 23,258 shares of the company's stock, valued at $16,513.18. Learn More on Robert J. DelAversano's trading history.

Who are OncoSec Medical's active insiders?

OncoSec Medical's insider roster includes Robert DelAversano (VP), Brian Leuthner (CEO), Daniel O'Connor (CEO), and Yuhang Zhao (Director). Learn More on OncoSec Medical's active insiders.

Are insiders buying or selling shares of OncoSec Medical?

In the last twelve months, OncoSec Medical insiders bought shares 2 times. They purchased a total of 12,000 shares worth more than $23,040.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 1,310 shares worth more than $1,389.23. The most recent insider tranaction occured on August, 5th when VP Robert J Delaversano sold 284 shares worth more than $201.64. Insiders at OncoSec Medical own 2.7 % of the company. Learn More about insider trades at OncoSec Medical.

Information on this page was last updated on 8/5/2022.

Robert J. DelAversano Insider Trading History at OncoSec Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2022Sell284$0.71$201.6423,258View SEC Filing Icon  
5/6/2022Sell274$0.83$227.4223,542View SEC Filing Icon  
2/9/2022Sell409$0.88$359.92View SEC Filing Icon  
11/1/2021Sell343$1.75$600.25View SEC Filing Icon  
8/2/2021Sell412$2.18$898.1624,568View SEC Filing Icon  
5/3/2021Sell453$4.86$2,201.5824,980View SEC Filing Icon  
See Full Table

Robert J. DelAversano Buying and Selling Activity at OncoSec Medical

This chart shows Robert J Delaversano's buying and selling at OncoSec Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OncoSec Medical Company Overview

OncoSec Medical logo
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Read More

Today's Range

Now: $0.73
Low: $0.71
High: $0.73

50 Day Range

MA: $0.79
Low: $0.71
High: $0.90

2 Week Range

Now: $0.73
Low: $0.67
High: $2.42


255 shs

Average Volume

79,387 shs

Market Capitalization

$28.64 million

P/E Ratio


Dividend Yield



A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.